Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
about
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsDebate: PCI vs CABG: a moving target, but we are gainingManagement of acute coronary syndromesGlycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarctionMedications for the treatment of acute coronary syndromesPro: Should aspirin be continued after cardiac surgery in the setting of thrombocytopenia?Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsRisk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI RegistryOptimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.A reliable plasma marker of platelet activation: does it exist?Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.Dealing with prognostic signature instability: a strategy illustrated for cardiovascular events in patients with end-stage renal diseaseNewer agents in antiplatelet therapy: a review.Novel uses for anti-platelet agents as anti-inflammatory drugs.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromesFuture innovations in anti-platelet therapies.The role of eptifibatide in patients undergoing percutaneous coronary intervention.Myocardial infarction: contemporary management strategies.Pharmacogenomics of platelet responsiveness to aspirin.Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.PROBING αIIbβ3: LIGAND INTERACTIONS BY DYNAMIC FORCE SPECTROSCOPY AND SURFACE PLASMON RESONANCE.The evolution of antiplatelet therapy in cardiovascular disease.Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor.Off-label use of drugs and devices in the neuroendovascular suite.Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.Cangrelor: a review on pharmacology and clinical trial development.Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.Optimizing the Use of Cangrelor in the Real World.Cangrelor for treatment during percutaneous coronary intervention.Intensity of antiplatelet therapy and percutaneous coronary intervention.Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood.Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.Antiplatelet drugs
P2860
Q24555072-B3A0C720-CA2F-4213-AB9D-EC4878B01DC4Q24799287-374A2864-5554-4644-8CC1-6BC6217BB4D2Q28189763-FC19C4D5-720A-4709-AA60-0A254FAE984CQ28193195-B36CBB68-A52A-43DC-8DD5-B73ED97DA3B9Q28193674-DF3F630A-ECE3-4E5B-B82E-2C97433A5DCCQ28194869-81D7F37E-714D-4A31-B557-12C29436E698Q28218351-94D4A745-AB69-43D0-8B69-D9B38B914372Q33434702-3EDE2A8A-0BBA-40BF-9A6E-FCDA403CDD40Q34272836-E98D5C41-C516-46FF-A6B8-9D532B9D86A8Q34712338-A308C7DE-EE99-4568-AD0F-22693278C6CFQ34733008-B92D91FA-5FBC-46C3-BBEE-139FC8EA8CB6Q35008537-F0A5F76E-F7BE-46DB-89BF-ACCEA6F5B010Q35773362-FC09384A-5FD6-4994-AFDE-4C2C4530907FQ36083333-FAB7520E-50AB-4FEE-AB66-F8C55805C458Q36085620-4859B51D-93DA-4A58-9710-8A8E32BAF183Q36171374-A741C638-9E4E-413A-916F-110FDADE1499Q36374457-869AD128-B53A-48E8-8522-B0B92BB05490Q36645766-1451794F-2B4A-4B92-86B8-5E4E12934F70Q36753593-8F4C8F8D-1182-4006-9C7B-8B128572C3B5Q36828151-36CACD1E-BE8E-4C90-9D4C-B793BB95ED26Q36863859-C6803C53-39DF-49B4-8F9D-E9614077463CQ36989841-574DE020-48F2-4421-9CAB-236310104185Q37174455-B950AAC9-CD1F-4E43-9FF5-EC6356379F35Q37211068-B172CAE2-AB9E-4BCA-9453-A4C51671D11DQ37900470-6C7AF8D0-A816-4A56-83E9-654C47527A33Q38073160-1AF907B2-C3DF-4D84-9EF3-08EE091F9A10Q38091856-7A12BAB1-E668-4A49-B962-91B427429D2FQ38118745-A9AF828B-C73F-4945-95DB-A22B5794ECF3Q38153779-85CE7396-BC13-47AC-AF52-9B0881CF9DF1Q38197732-669339BA-46C8-4F87-8DED-CCD108659BEDQ38817125-139BA769-50B8-4BF7-A55A-0DBB1730C4F4Q39204251-41EA4697-292C-4D9A-BB7C-2641D514C7DCQ42535451-2E391318-BE86-4493-AD24-A73F789E7DCEQ44445340-20347F69-676B-4E50-91A7-6E946397A381Q44563411-CD884BEA-2A4B-42B7-BFAE-20DC57AB6A58Q46328333-182B3F8F-DA39-446A-B9CB-B87D06FE5B41Q46591692-94D8D183-AD68-4413-B09A-980EA41F8948Q47142348-97D44823-2046-40C4-8D8F-F9742AFCE676Q58481433-F1D28AE0-BE3A-476C-B34A-BC56CCA39C5F
P2860
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@ast
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@en
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@nl
type
label
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@ast
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@en
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@nl
prefLabel
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@ast
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@en
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@nl
P356
P1476
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
@en
P2093
P304
P356
10.1001/JAMA.284.12.1549
P407
P50
P577
2000-09-01T00:00:00Z